Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Vancomycin Hydrochloride for Injection, USP 500 mg per vial, NDC-71288-022-11, and Vancomycin Hydrochloride for Injection, USP 1 g per vial, NDC-71288-023-21, in single-dose vials. This is in addition to the current on-market strengths of 750 mg, 5 g, and 10 g.
Meitheal will offer Vancomycin Hydrochloride for Injection, USP 500 mg and Vancomycin Hydrochloride for Injection, USP 1 g in pack of 10 vials.
ABOUT VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP
Vancomycin Hydrochloride for Injection is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin hydrochloride-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin Hydrochloride for Injection is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly.
For full prescribing information, please click on the following link.
Learn more about Vancomycin Hydrochloride for Injection, USP.
